<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778075</url>
  </required_header>
  <id_info>
    <org_study_id>CR100924</org_study_id>
    <secondary_id>TRAMCTPAI1003</secondary_id>
    <nct_id>NCT01778075</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Bioequivalence of a New ULTRACET Extended Release (ER) Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition</brief_title>
  <official_title>A Single Dose, Open-Label, Randomized, Two-Way Crossover Pivotal Study to Assess the Bioequivalence of a New ULTRACET ER Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Korea, Ltd., Korea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Korea, Ltd., Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bioequivalence of a newly developed ULTRACET
      extended-release (ER) tablet of tramadol hydrochloride and acetaminophen, to the current
      marketed ULTRACET ER tablet, in healthy participants under fasted condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of racemic tramadol (Period 1)</measure>
    <time_frame>Up to 48 hours following the administration of study drug on Day 1 of Period 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of acetaminophen (Period 1)</measure>
    <time_frame>Up to 48 hours following the administration of study drug on Day 1 of Period 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of racemic tradamdol (Period 2)</measure>
    <time_frame>Up to 48 hours following the administration of study drug on Day 1 of Period 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of acetaminophen (Period 2)</measure>
    <time_frame>Up to 48 hours following the administration of study drug on Day 1 of Period 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events as a measure of safety and tolerability</measure>
    <time_frame>Approximately 5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment sequence AB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)</intervention_name>
    <description>Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.</description>
    <arm_group_label>Treatment sequence AB</arm_group_label>
    <arm_group_label>Treatment sequence BA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)</intervention_name>
    <description>Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.</description>
    <arm_group_label>Treatment sequence AB</arm_group_label>
    <arm_group_label>Treatment sequence BA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed an informed consent document indicating they understand the purpose of and
             procedures required for the study and are willing to participate

          -  Must agree to use an adequate contraception method as deemed appropriate by the
             investigator (e.g., vasectomy, double-barrier, partner using effective contraception)
             and to not donate sperm during the study and for 3 months after receiving the last
             dose of study drug

          -  Body mass index (weight [kg]/height2 [m]2) between 18.5 and 30 kg/m2 (inclusive), and
             body weight not less than 50 kg

          -  Blood pressure (after the participant is sitting for 5 minutes) between 90 and 140 mm
             Hg systolic, inclusive, and no higher than 90 mm Hg diastolic

          -  A 12-lead electrocardiogram (ECG) consistent with normal cardiac function, including
             sinus rhythm, pulse rate between 45 and 90 bpm, QTc interval &lt;= 450 ms, QRS interval
             of &lt;110 ms, PR interval &lt;200 ms, and morphology consistent with healthy cardiac
             function

        Exclusion Criteria:

          -  History of or current clinically significant medical illness including (but not
             limited to) cardiac arrhythmias or other cardiac disease, hematologic (blood) disease,
             coagulation disorders (including any abnormal bleeding), lipid abnormalities,
             significant lung disease (including bronchospastic respiratory disease), diabetes
             mellitus, kidney or liver insufficiency, thyroid disease, neurologic or psychiatric
             disease, infection, or any other illness that the investigator considers should
             exclude the participant or that could interfere with the interpretation of the study
             results

          -  Clinically significant abnormal values for hematology, clinical chemistry or
             urinalysis at screening or at admission to the study center as deemed appropriate by
             the investigator

          -  Clinically significant abnormal physical examination, vital signs or 12-lead ECG at
             screening (or at admission to the study center) as deemed appropriate by the
             investigator

          -  Use of any prescription or nonprescription medication (including vitamins and herbal
             supplements), except for oral contraceptives and hormonal replacement therapy within
             14 days before the first dose of the study drug is scheduled

          -  History of, or reason to believe a participant has a history of, drug or alcohol abuse
             within the past 5 years
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Korea, Ltd., Korea Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Korea, Ltd., Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=3592&amp;filename=CR100924_CSR.pdf</url>
    <description>A Single-Dose, Open-Label, Randomized, Two-Way Crossover Pivotal Study to Assess the Bioequivalence of a New ULTRACET ER Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Conditions</description>
  </link>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2013</study_first_submitted>
  <study_first_submitted_qc>January 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <last_update_submitted>February 7, 2014</last_update_submitted>
  <last_update_submitted_qc>February 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Ultracet extended release (ER)</keyword>
  <keyword>Tramadol hydrochloride</keyword>
  <keyword>Acetaminophen</keyword>
  <keyword>Bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

